Company Overview
Snapshot
Founded in January 2024 by Arnout Schepers, TenAces Biosciences operates with 1-10 employees. The company has secured one funding round from two investors, AION Labs and Israel Biotech Fund, to develop its molecular glue therapeutics platform.
Business overview
TenAces Biosciences is a biopharmaceutical company specializing in the development of molecular glue therapeutics. Its core technology involves small molecules that induce or stabilize interactions between E3 ligases and target proteins, accelerating protein degradation. The company leverages machine learning, 3D modeling, and virtual compound screening to rationally design these molecular glues for various diseases, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2024, TenAces Biosciences was launched by AION Labs and Israel Biotech Fund. This launch signals strong industry validation for TenAces' novel approach to molecular glue discovery, leveraging machine learning to enhance targeted protein degradation. For investors, this indicates a strategic entry into the drug discovery market with significant backing and a technology poised to accelerate therapeutic development.
Log in to access full profile ›Company Intelligence Q&A
- What is TenAces Biosciences' core focus?
- TenAces Biosciences is focused on the development of molecular glue therapeutics, which are small molecules designed to induce or stabilize interactions between E3 ligases and target proteins for accelerated protein degradation.
- When was TenAces Biosciences founded?
- TenAces Biosciences was founded in January 2024.
- Who are the founders of TenAces Biosciences?
- Arnout Schepers is a founder of TenAces Biosciences.
- Which investors participated in TenAces Biosciences' funding round?
- In January 2024, TenAces Biosciences secured funding from AION Labs and Israel Biotech Fund.
- What technology does TenAces Biosciences use for drug discovery?
- TenAces Biosciences utilizes machine learning, 3D modeling, and virtual compound screening to rationally design molecular glues for various diseases.